PT - JOURNAL ARTICLE AU - Padoan, Andrea AU - Dall’Olmo, Luigi AU - Rocca, Foscarina della AU - Barbaro, Francesco AU - Cosma, Chiara AU - Basso, Daniela AU - Cattelan, Annamaria AU - Cianci, Vito AU - Plebani, Mario TI - Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers AID - 10.1101/2021.03.24.21254240 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.24.21254240 4099 - http://medrxiv.org/content/early/2021/03/26/2021.03.24.21254240.short 4100 - http://medrxiv.org/content/early/2021/03/26/2021.03.24.21254240.full AB - Background Vaccine-induced population immunity is a key global strategy to control coronavirus disease 2019 (COVID-19). The rapid implementation and availability of several COVID-19 vaccines is now a global health-care priority but more information about humoral responses to single- and double-dose vaccine is neededMethods 163 health care workers (HCW) of the Padua University Hospitals, who underwent a complete vaccination campaign with BNT162b2 vaccine were asked to collect serum samples at 12 (t12) and 28 (t28) days after the first inoculum to allow the measurement of SARS-CoV-2 Antibodies (Ab) using chemiluminescent assays against the spike (S) protein and the Receptor Binding Domain (RBD) of the virus, respectively.Results Significant differences were found at t12 for infection-naïve and subjects with previous-natural infection who present higher values of specific antibodies, while no significant differences have been found between t12 and t28. No statistically significant difference was found between male and female, while lower Ab levels have been observed in subjects older than 60 years at t12 but not at t28.Conclusions Our study confirms observed differences in vaccine responses between infection-naïve and subjects with previous natural infection at t12 but not for a longer time. The influence of sex and age deserves further studies, even if the relationship with age seems particularly significant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was performed in accordance with the Declaration of Helsinki and all participants gave informed consent (Institutional Review Board of the University of Padua protocol nr 7862).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon request